Skip to main content

Table 2 Transition probabilities from the decision tree to the Markov model

From: Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain

Parameter Transition probability (Palivizumab and no prophylaxis) Calculation (see Table 1 for efficacy inputs)
MA-RSV
 No sequelae, % 56.1 (1 − p Asthma ) × (1 − p AS )
 Asthma, % 6.4 p Asthma  × (1 − p AS )
 Allergic sensitization, % 33.6 (1 − p Asthma  ) × p AS
 Asthma and allergic sensitization, % 3.9 p Asthma  × p AS
RSV-H
 No sequelae, % 38.1 (1 − p Asthma ) × (1 − p AS )
 Asthma, % 18.4 p Asthma  × (1 − p AS )
 Allergic sensitization, % 29.3 (1 − p Asthma  ) × p AS
 Asthma and allergic sensitization, % 14.2 p Asthma  × p AS
  1. Abbreviations: RSV, respiratory syncytial virus; MA-RSV, medically attended RSV infection; AS, allergic sensitization; RSV-H, RSV infection resulting in hospitalization